A missense mutation in the fabB (β-ketoacyl-acyl carrier protein synthase I) gene confers thiolactomycin resistance to Escherichia coli

被引:30
作者
Jackowski, S
Zhang, YM
Price, AC
White, SW
Rock, CO
机构
[1] St Jude Childrens Res Hosp, Prot Sci Div, Dept Infect Dis, Memphis, TN 38105 USA
[2] St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA
[3] Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA
关键词
D O I
10.1128/AAC.46.5.1246-1252.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Thiolactomycin (TLM) is an antibiotic that inhibits bacterial type H fatty acid synthesis at the condensing enzyme step, and beta-ketoacyl-acyl carrier protein synthase I (FabB) is the relevant target in Escherichia coli. TLM resistance is associated with the upregulation of efflux pumps. Therefore, a tolC knockout mutant (strain ANS1) was constructed to eliminate the contribution of type I secretion systems to TLM resistance. Six independent TLM-resistant clones of strain ANS1 were isolated, and all possessed the same missense mutation in the fabB gene (T1168G) that directed the expression of a mutant protein, FabB(F390V). FabB(F390V) was resistant to TLM in vitro. Leucine is the only other amino acid found at position 390 in nature, and the Staphylococcus aureus FabF protein, which contains this substitution, was sensitive to TLM. Structural modeling predicted that the CG2 methyl group of the valine side chain interfered with the positioning of the C11 methyl on the isoprenoid side chain of TLM in the binary complex, whereas the absence of a bulky methyl group on the leucine side chain permitted TLM binding. These data illustrate that missense mutations that introduce valine at position 390 confer TLM resistance while maintaining the vital catalytic properties of FabB.
引用
收藏
页码:1246 / 1252
页数:7
相关论文
共 42 条
[1]  
BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
[2]   CELL-SURFACE PROTEINS OF ESCHERICHIA-COLI [J].
BOOTH, BR .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1980, 94 (04) :1029-1036
[3]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[4]   Type I secretion and multidrug efflux: transport through the TolC channel-tunnel [J].
Buchanan, SK .
TRENDS IN BIOCHEMICAL SCIENCES, 2001, 26 (01) :3-6
[5]   VALIDATION OF THE GENERAL-PURPOSE TRIPOS 5.2 FORCE-FIELD [J].
CLARK, M ;
CRAMER, RD ;
VANOPDENBOSCH, N .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 1989, 10 (08) :982-1012
[6]  
CRONAN JE, 1996, ESCHERICHIA COLI SAL, P612
[7]   INHIBITION OF FATTY-ACID SYNTHESIS BY ANTIBIOTIC CERULENIN - SPECIFIC INACTIVATION OF BETA-KETOACYL-ACYL CARRIER PROTEIN SYNTHETASE [J].
DAGNOLO, G ;
ROSENFELD, IS ;
AWAYA, J ;
OMURA, S ;
VAGELOS, PR .
BIOCHIMICA ET BIOPHYSICA ACTA, 1973, 326 (02) :155-166
[8]   THIOLACTOMYCIN RESISTANCE IN ESCHERICHIA-COLI IS ASSOCIATED WITH THE MULTIDRUG-RESISTANCE EFFLUX PUMP ENCODED BY EMRAB [J].
FURUKAWA, H ;
TSAY, JT ;
JACKOWSKI, S ;
TAKAMURA, Y ;
ROCK, CO .
JOURNAL OF BACTERIOLOGY, 1993, 175 (12) :3723-3729
[9]  
GARWIN JL, 1980, J BIOL CHEM, V255, P1949
[10]   ANTIMICROBIAL ACTIVITIES OF THIOLACTOMYCIN AGAINST GRAM-NEGATIVE ANAEROBES ASSOCIATED WITH PERIODONTAL-DISEASE [J].
HAMADA, S ;
FUJIWARA, T ;
SHIMAUCHI, H ;
OGAWA, T ;
NISHIHARA, T ;
KOGA, T ;
NEHASHI, T ;
MATSUNO, T .
ORAL MICROBIOLOGY AND IMMUNOLOGY, 1990, 5 (06) :340-345